Seven Eight Capital, LP Sage Therapeutics, Inc. Transaction History
Seven Eight Capital, LP
- $927 Million
- Q1 2024
A detailed history of Seven Eight Capital, LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Seven Eight Capital, LP holds 45,494 shares of SAGE stock, worth $490,425. This represents 0.09% of its overall portfolio holdings.
Number of Shares
45,494
Previous 20,884
117.84%
Holding current value
$490,425
Previous $452,000
88.5%
% of portfolio
0.09%
Previous 0.05%
Shares
10 transactions
Others Institutions Holding SAGE
# of Institutions
222Shares Held
52.7MCall Options Held
207KPut Options Held
191K-
Vanguard Group Inc Valley Forge, PA5.75MShares$62 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$59.1 Million1.65% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$52.7 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA4.75MShares$51.2 Million0.02% of portfolio
-
State Street Corp Boston, MA4.49MShares$48.5 Million0.0% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $641M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...